GlassScriptPhysician profile
Tayler Acton
NPI 1538796172
$2,329.61
in general payments reported to CMS, 2019-2025
16 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $563 · 2023: $773 · 2024: $646 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $446.76 | 2024-2025 | Corevalve Evolut R, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $340.49 | 2022-2023 | Eliquis, Camzyos |
| Abiomed | $264.28 | 2022-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.64 | 2024-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $156.35 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $129.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.80 | 2023 | Airsupra, Imfinzi |
| Novo Nordisk INC | $124.26 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $123.05 | 2023 | |
| Novartis Pharmaceuticals Corporation | $113.44 | 2023 | |
| United Therapeutics Corporation | $105.17 | 2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.69 | 2023 | Lifevest |
| Paratek Pharmaceuticals, INC. | $37.10 | 2022-2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.54 | 2023 | Xifaxan |
| Ferring Pharmaceuticals INC. | $20.87 | 2023 | Rebyota |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $17.82 | 2023 | Fisher & Paykel Healthcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayler Acton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.